Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

J. C. Goh, J. Coward, B. Gao, I. Pires Da Silva, M. Voskoboynik, D. Day, A. Body, H. K. Gan, X. Li, J. Sun, C. Fei, L. Yang, M. Millward

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S1446-S1447
Number of pages2
JournalAnnals of Oncology
Publication statusPublished - Dec 2021
EventESMO Immuno-Oncology Congress 2021 -
Duration: 8 Dec 202111 Dec 2021

Cite this